Drug intelligence / Profile preview

DW1031

Development stage: Preclinical
Lead developer: Dongwha Pharmaceutical
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

DW1031 is a targeted protein degrader (TPD) being developed by Dong-Wha Pharmaceutical for the treatment of fibrotic diseases. The drug utilizes a proteolysis-targeting chimera (PROTAC) or similar degradation mechanism to selectively eliminate a novel, undisclosed protein target that is implicated in the pathogenesis of fibrosis. By leveraging the cellular ubiquitin-proteasome system to degrade the disease-causing protein rather than simply inhibiting it, DW1031 aims to provide a more potent and durable therapeutic effect. As of current pipeline reports, the program has progressed through hit identification and is in the preclinical development stage.

Beyond the preview

Go deeper on DW1031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW1031.

Explore the full profile